Skip to main content

Advertisement

Table 2 Relative hazards of ALT elevation >200 IU/l from fitting a Cox regression model

From: Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study

  Crude and adjusted relative hazards of developing ALT>200 IU/l
Biomarker Crude RH (95% CI) p-value Adjusted*RH (95% CI) p-value Adjusted**RH (95% CI) p-value
CD8CD38+DR+, %       
<=48% 1.0   1.0   1.0  
>48% 0.30 (0.03, 2.93) 0.303 0.17 (0.01, 1.91) 0.150 0.09 (0.01, 1.44) 0.088
not measured 1.24 (0.37, 4.20) 0.726 1.12 (0.32, 3.94) 0.865 0.76 (0.18, 3.27) 0.711
IL-6, pg/ml       
<=1.1 1.0   1.0   1.0  
>1.1 2.77 (0.98, 7.87) 0.056 1.82 (0.61, 5.43) 0.281 1.56 (0.46, 5.32) 0.481
not measured 2.00 (0.61, 6.57) 0.251 1.79 (0.53, 6.07) 0.351 2.19 (0.18, 27.33) 0.543
LPS, pg/ml       
<=126 1.0   1.0   1.0  
>126 1.26 (0.44, 3.59) 0.669 0.77 (0.21, 2.83) 0.697 0.39 (0.08, 1.84) 0.235
not measured 0.66 (0.25, 1.78) 0.417 0.67 (0.22, 2.04) 0.478 0.31 (0.08, 1.28) 0.107
sCD14, mg/ml       
<=3.6 1.0   1.0   1.0  
>3.6 0.82 (0.32, 2.07) 0.669 0.79 (0.29, 2.19) 0.651 0.84 (0.25, 2.82) 0.778
not measured 0.98 (0.33, 2.86) 0.967 1.13 (0.35, 3.59) 0.842 0.80 (0.03, 25.38) 0.900
TNF-alfa, pg/ml       
<=2.3 1.0   1.0   1.0  
>2.3 4.01 (1.32, 12.21) 0.014 2.14 (0.64, 7.15) 0.217 2.03 (0.57, 7.29) 0.276
not measured 2.48 (0.67, 9.26) 0.175 1.82 (0.46, 7.17) 0.394 1.66 (0.10, 28.78) 0.728
  1. *All models (a separate one for each biomarker) adjusted for age, CD4, VL, baseline ALT, year of sample, duration of HIV infection at the date of sample.
  2. **Further mutually adjusted for all biomarkers.